Seres Therapeutics, Inc. (MCRB) Bundle
A Brief History of Seres Therapeutics, Inc. (MCRB)
Foundation and Early Development
Seres Therapeutics, Inc. was founded in 2010, emerging from research at Harvard University and the Massachusetts Institute of Technology (MIT). The company's primary focus is on microbiome-based therapeutics, which leverage the human microbiome as a source of therapeutic agents.
Initial Public Offering (IPO)
On October 27, 2014, Seres Therapeutics went public, raising approximately $130 million through its initial public offering on the NASDAQ under the ticker symbol MCRB.
Key Product Development
Seres' lead product candidate, SER-109, is designed for the prevention of recurrent Clostridium difficile infection (CDI). In December 2020, the company reported top-line results from its Phase 3 study, where SER-109 demonstrated a statistically significant reduction in CDI recurrence compared to placebo.
Financial Performance
As of Q3 2023, Seres Therapeutics reported total revenues of $5.3 million, primarily attributed to collaboration agreements. The total operating expenses for the same period were $24.8 million, leading to a net loss of $19.5 million.
| Year | Revenue ($ millions) | Operating Expenses ($ millions) | Net Loss ($ millions) |
|---|---|---|---|
| 2020 | 0.4 | 93.1 | (92.7) |
| 2021 | 3.6 | 104.5 | (100.9) |
| 2022 | 1.2 | 82.9 | (81.7) |
| 2023 (Q3) | 5.3 | 24.8 | (19.5) |
Research Collaborations and Partnerships
Seres has engaged in multiple collaborations to advance its research initiatives. Notably, in March 2021, Seres entered into a collaboration agreement with Nestlé Health Science to develop microbiome-based therapies for metabolic disorders.
Recent Developments
In August 2023, Seres announced the submission of its Biologics License Application (BLA) for SER-109 to the U.S. Food and Drug Administration (FDA) seeking approval for the treatment of recurrent CDI. The company plans to expand its pipeline with additional microbiome-based therapies targeting various indications.
Stock Performance and Market Valuation
As of October 2023, Seres Therapeutics has a market capitalization of approximately $200 million. The stock price has experienced volatility, reflecting both clinical trial outcomes and market conditions.
| Date | Stock Price ($) | Market Cap ($ millions) |
|---|---|---|
| January 1, 2023 | 3.00 | 150 |
| June 1, 2023 | 2.50 | 125 |
| September 1, 2023 | 4.00 | 200 |
Future Prospects
Looking forward, Seres Therapeutics aims to solidify its leadership in the microbiome therapeutics space, with a focus on clinical trials and regulatory submissions to drive future growth.
A Who Owns Seres Therapeutics, Inc. (MCRB)
Ownership Structure
Ownership Structure
As of the latest SEC filings, the ownership structure of Seres Therapeutics, Inc. (MCRB) comprises institutional investors, retail investors, and company insiders. The distribution of ownership is as follows:
| Owner Type | Percentage Ownership |
|---|---|
| Institutional Investors | 83.5% |
| Insiders | 1.2% |
| Retail Investors | 15.3% |
Major Institutional Investors
The following table lists the major institutional shareholders of Seres Therapeutics:
| Institution | Shares Owned | Percentage of Total Shares |
|---|---|---|
| The Vanguard Group | 2,380,000 | 14.9% |
| BlackRock, Inc. | 2,120,000 | 13.4% |
| State Street Corporation | 1,750,000 | 11.1% |
| FMR LLC (Fidelity) | 1,500,000 | 9.5% |
| Geode Capital Management | 1,000,000 | 6.4% |
Insider Ownership
The insider ownership data indicates the percentage of shares held by the executive team and board members.
| Insider Name | Position | Shares Owned |
|---|---|---|
| Eric Shaff | CEO | 150,000 |
| David Steinberg | Chairman | 100,000 |
| Tamer Elsayed | CFO | 50,000 |
Recent Stock Performance
The stock performance of Seres Therapeutics reflects market sentiments and ownership changes:
| Date | Closing Price | Market Cap |
|---|---|---|
| October 20, 2023 | $5.12 | $325 million |
| October 13, 2023 | $4.85 | $300 million |
| October 06, 2023 | $4.70 | $290 million |
Shareholder Meetings
Shareholder meetings provide insights into management decisions and ownership discussions. The most recent meeting was held on:
- Date: June 15, 2023
- Key Topics: Executive compensation, stock options, and future strategic directions
Stock Options and Incentives
Insider stock options contribute significantly to ownership statistics:
| Insider Name | Options Granted | Expiration Date |
|---|---|---|
| Eric Shaff | 200,000 | December 31, 2028 |
| David Steinberg | 100,000 | December 31, 2028 |
| Tamer Elsayed | 50,000 | December 31, 2028 |
Seres Therapeutics, Inc. (MCRB) Mission Statement
Overview of Seres Therapeutics
Seres Therapeutics, Inc. is a biotechnology company focused on developing novel therapeutics based on its proprietary microbiome platform. The company is publicly listed on the NASDAQ under the ticker symbol MCRB.
Mission Statement
Seres Therapeutics is dedicated to transforming the lives of patients with serious diseases by harnessing the power of the microbiome. The mission emphasizes innovation, scientific integrity, and commitment to patient health.
Strategic Goals
- Accelerate the development of microbiome-based therapies.
- Lead in microbiome research and clinical trials.
- Establish partnerships that enhance product development.
- Deliver transformative therapies to patients.
Financial Performance
As of the latest quarterly report, Seres Therapeutics has reported the following financial highlights:
| Year | Revenue ($ millions) | Net Loss ($ millions) | Cash and Cash Equivalents ($ millions) |
|---|---|---|---|
| 2022 | 12.5 | -88.7 | 154.2 |
| 2023 (Q2) | 15.0 | -30.5 | 142.0 |
| 2023 (Q3, projected) | 17.5 | -33.0 | 136.0 |
Product Pipeline
Seres Therapeutics' product pipeline includes:
| Product Candidate | Indication | Phase | Projected Launch Date |
|---|---|---|---|
| SER-109 | Recurrent Clostridium difficile infection | Phase 3 | 2024 |
| SER-287 | Ulcerative Colitis | Phase 2 | 2025 |
| SER-155 | Prevention of infections post-transplant | Phase 1 | 2026 |
Recent Developments
In 2023, Seres Therapeutics reported significant progress in its clinical trials:
- Successful completion of Phase 2 trials for SER-287 with promising results.
- Initiated new collaborations with leading research institutions.
- Received FDA Fast Track Designation for SER-109 in December 2022.
Commitment to Research and Innovation
Seres Therapeutics invests heavily in R&D to maintain its leading position in microbiome science. In the fiscal year 2023, R&D expenditures were approximately $70 million.
Market Position
The market for microbiome-based therapeutics is projected to reach $5 billion by 2025. Seres Therapeutics aims to secure a substantial share of this growing market through its innovative product offerings.
Conclusion on Financial Health
As of recent financial statements, Seres Therapeutics maintains a healthy balance sheet with a strong cash position, enabling continued investment in its product pipeline and research initiatives.
How Seres Therapeutics, Inc. (MCRB) Works
Overview of Seres Therapeutics
Seres Therapeutics, Inc. (NASDAQ: MCRB) is a biotechnology company focusing on developing microbiome-based therapeutics for diseases, particularly in the area of gastrointestinal diseases. The company's lead product candidate, SER-109, is designed to treat recurrent Clostridioides difficile infection (CDI).
Business Model
Seres operates on a model that emphasizes research and development in microbiome therapeutics. The company conducts extensive clinical trials to prove the safety and efficacy of its products. Partnerships with academic institutions and pharmaceutical companies play a critical role in its research efforts.
Financial Performance
As of Q3 2023, Seres Therapeutics reported a total revenue of $10.3 million, primarily derived from research collaborations and grant funding. The company's operating expenses for the same period were approximately $29.4 million, resulting in a net loss of $19.1 million.
| Financial Metric | Q3 2022 | Q3 2023 |
|---|---|---|
| Total Revenue | $5.2 million | $10.3 million |
| Operating Expenses | $25.7 million | $29.4 million |
| Net Loss | $20.5 million | $19.1 million |
Research and Development Pipeline
Seres has a robust pipeline of products in various stages of development. Key candidates include:
- SER-109: For recurrent CDI, currently in Phase 3 trials.
- SER-155: Aimed at improving outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation, in Phase 1 trials.
- SER-287: Targeting ulcerative colitis, in Phase 1 trials.
Market Position and Competitors
Seres is positioned within a competitive landscape of microbiome therapeutics. Key competitors include:
- Synlogic, Inc.
- Second Genome, Inc.
- Ferring Pharmaceuticals
As of October 2023, the global microbiome therapeutics market is valued at approximately $565.7 million and is projected to reach $1.9 billion by 2028, growing at a CAGR of 20.0%.
Stock Performance
The stock price of Seres Therapeutics has shown volatility. As of October 2023, the market capitalization stands at approximately $530 million. The share price fluctuated between $3.00 and $7.50 in 2023.
Collaborations and Partnerships
Seres has entered collaborations to enhance its research efforts, including:
- Partnership with Nestlé Health Science to develop microbiome-based products.
- Collaboration with Harvard University for pioneering research in gut microbiome.
Regulatory Status
Seres has received Breakthrough Therapy Designation from the FDA for SER-109, expediting the development process. The company expects to submit a Biologics License Application (BLA) by the end of 2024.
Future Outlook
Looking ahead, Seres plans to advance its pipeline and expand clinical trials while exploring additional indications for its microbiome therapies. The company aims to establish itself as a leader in this emerging field of medicine.
How Seres Therapeutics, Inc. (MCRB) Makes Money
Revenue Streams
Revenue Streams
Seres Therapeutics, Inc. primarily generates revenue through its clinical development partnerships, licensing agreements, and potential product commercialization. The company's focus is on developing microbiome-based therapies for various diseases.
Partnership and Collaboration Agreements
In 2020, Seres Therapeutics secured a partnership with Nestlé Health Science to develop microbiome-based products. This collaboration includes milestones and royalty payments that contribute to the company’s revenue model. The agreement could potentially provide up to $400 million in total milestones.
Additionally, Seres has entered into agreements with multiple pharmaceutical companies, which include upfront payments and royalties based on future sales.
Product Candidates and Pipeline
The main product candidates are as follows:
- SER-109: This is a microbiome therapeutic for the prevention of recurrent Clostridium difficile infection. The product is in phase 3 clinical trials, with a projected launch in the market by 2024.
- SER-287: This candidate targets Ulcerative Colitis and is currently in phase 2 trials.
- SER-155: Targeting immune-oncology patients, this candidate is also in the development phase.
Financial Overview
As of the end of Q2 2023, Seres Therapeutics reported total revenues of $8.6 million, a significant increase from $3.5 million reported in the same quarter of 2022. The revenue growth is mainly attributed to collaboration revenues.
The following table summarizes the financial performance of Seres over the last three years:
| Year | Total Revenue | Net Loss | Cash and Cash Equivalents |
|---|---|---|---|
| 2021 | $6.0 million | ($70.1 million) | $156.7 million |
| 2022 | $12.4 million | ($72.3 million) | $112.5 million |
| 2023 (Q2) | $8.6 million | ($23.4 million) | $95.5 million |
Research and Development Expenses
Research and development expenses are significant for Seres. In Q2 2023, these expenses were approximately $20 million, reflecting the costs associated with ongoing clinical trials and development activities.
Market Potential and Future Outlook
The global microbiome market is projected to reach $1.5 billion by 2025. With an increasing focus on microbiome-based therapies, Seres is well-positioned to capitalize on this growing market.
In 2023, analysts project that, if the clinical trials are successful, SER-109 alone could generate peak annual sales of $1 billion.
Seres Therapeutics, Inc. (MCRB) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support